SPI-GCF-104: Same Day Administration of Eflapegrastim to Treat Neutropenia in Patients Being Treated With Neo/Adjuvant Docetaxel Plus Cyclophosphamide
Condition: Breast Cancer
Sponsor: Spectrum Pharmaceuticals, Inc.
Full Title
SPI-GCF-104: Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After the Same-Day, Varying Dosing Time Schedules of Eflapegrastim Administration in Patients with Breast-Cancer Receiving Docetaxel and Cyclophosphamide
Study Treatment
Human granulocyte colony-stimulating factor analog Eflapegrastim
Eligibility/Info
For patients with newly diagnosed, operable stage I-IIIA breast cancer with plans for neoadjuvant or adjuvant treatment with cyclophosphamide and docetaxel in combination.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
